IP Library Granted Patent US 11,046,669
Granted Patent B2
US 11,046,669 · App. 16/453,418 · Granted Jun 29, 2021

Inhibitors of (α-v)(β-6) integrin

Inventors: Bryce A. Harrison (Framingham, MA); Matthew G. Bursavich (Needham, MA); Mark Brewer (Wallingford, GB); Aleksey I. Gerasyuto (Flemington, NJ); Kristopher N. Hahn (Medford, MA); Kyle D. Konze (Brooklyn, NY); Fu-Yang Lin (Sudbury, MA); Blaise S. Lippa (Newton, MA); Alexey A. Lugovskoy (Belmont, MA); Bruce N. Rogers (Belmont, MA); Mats A. Svensson (New York, NY); Dawn M. Troast (Bedford, MA)
Assignee: Morphic Therapeutic, Inc.
C07D401/12C07D471/04C07D471/08C07D487/08C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,046,669
App. No.
16/453,418
Granted
Jun 29, 2021
Kind
B2
Abstract

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

Claims (48)

1. A compound of formula (I):

A-B—C  (I)

wherein:

A is

B is -alkylene-C(O)N(R)—;

C is

R is H;

R 1 is H;

R 2 is H, alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cycloalkyl, -alkylene-alkoxy, alkylene-aryl, or heterocycloalkyl; and

R 3 is H;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein R 2 is H, (C 1 -C 4 )alkyl, cyclopropyl, CH 2 OMe, phenyl, —CH 2 Ph, pyridinyl, or indolyl.

3. The compound of claim 1 , wherein R 2 is unsubstituted phenyl.

4. The compound of claim 1 , wherein R 2 is substituted phenyl.

5. The compound of claim 4 , wherein the substituted phenyl is substituted with one or more independent instances of alkoxy, OH, halide, —N(H)C(O)alkyl, —C(O)NH 2 , or —C(O)alkyl.

6. The compound of claim 5 , wherein the substituted phenyl is substituted with at least one halide.

7. The compound of claim 6 , wherein the halide is Cl.

8. The compound of claim 1 , wherein the compound is selected from the group consisting of:

9. The compound of claim 1 , wherein the compound is:

10. The compound of claim 1 , wherein the compound is selected from the group consisting of:

11. The compound of claim 1 , wherein the compound is:

12. The compound of claim 1 , wherein the compound is selected from the group:

13. The compound of claim 1 , wherein the compound is:

14. The compound of claim 1 , wherein

a. alkylene in B is n-propyl or n-butyl; and

b. R 2 is selected from unsubstituted phenyl, or phenyl substituted with one or more of alkoxy, alkyl, cycloalkyl, or halide.

15. The compound of claim 1 , wherein

R 2 is H.

16. The compound of claim 1 , wherein the compound is:

17. The compound of claim 1 , wherein the compound is:

18. The compound of claim 1 , wherein R 2 is selected from H, Me, unsubstituted phenyl, or phenyl substituted with one or more of alkoxy, alkyl, cycloalkyl, or halide.

19. The compound of claim 1 , wherein R 2 is H, alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

20. The compound of claim 1 , wherein R 2 is selected from H, Me, unsubstituted phenyl, or phenyl substituted with one or more of methoxy, methyl, cyclopropyl, or halide.

21. The compound of claim 1 , wherein alkylene in B is propyl or butyl.

22. The compound of claim 1 , wherein alkylene in B is n-propyl or n-butyl.

23. The compound of claim 1 , wherein C is

24. The compound of claim 23 , wherein R 2 is H, alkyl, or aryl.

25. The compound of claim 24 , wherein alkylene in B is propyl or butyl.

26. The compound of claim 24 , wherein R 2 is H, methyl or unsubstituted phenyl and alkylene in B is n-propyl or n-butyl.

27. The compound of claim 1 , wherein alkylene in B is n-propyl or n-butyl.

28. The compound of claim 1 , wherein C is

29. The compound of claim 28 , wherein R 2 is H, alkyl, or aryl.

30. The compound of claim 28 , wherein R 2 is unsubstituted phenyl and alkylene in B is n-propyl or n-butyl.

31. The compound of claim 1 , wherein C is

32. The compound of claim 31 , wherein R 2 is H, alkyl, or aryl.

33. The compound of claim 32 , wherein alkylene in B is propyl or butyl.

34. The compound of claim 31 , wherein R 2 is unsubstituted phenyl or phenyl substituted with alkoxy, alkyl or halogen, and the alkylene in B is n-propyl or n-butyl.

35. The compound of claim 34 , wherein R 2 is unsubstituted phenyl or phenyl substituted with methoxy, and alkylene in B is n-propyl.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2019
From: BREWER, MARK; GERASYUTO, ALEKSEY I.; KONZE, KYLE D.; SVENSSON, MATS A.
To: SCHRÖDINGER, INC.
Reel/Frame 049624/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2019
From: HARRISON, BRYCE A.; BURSAVICH, MATTHEW G.; HAHN, KRISTOPHER N.; LIN, FU-YANG; LIPPA, BLAISE S.; LUGOVSKOY, ALEXEY A.; ROGERS, BRUCE N.; TROAST, DAWN M.
To: MORPHIC THERAPEUTIC, INC.
Reel/Frame 049624/0229 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2019
From: SCHRÖDINGER, INC.
To: SCHRÖDINGER, LLC
Reel/Frame 049624/0262 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2019
From: SCHRÖDINGER, LLC
To: MORPHIC THERAPEUTIC, INC.
Reel/Frame 049624/0273 →
Continuity (3)
Continuation 15906745 · Feb 27, 2018
Provisional Application 62464693 · Feb 28, 2017
Related Publication 20200157075A1 · May 21, 2020
Cited By (4)
US 12,415,796 US 12,459,942 US 12,528,803 US 12,552,786